Pharmaceutics International, Inc. (Pii), a Contract Development Manufacturing Organization (CDMO) based in Hunt Valley, Maryland, received notification on June 4, 2018 from the Medicines and Health Care products Regulatory Agency (“MHRA”) that the previously restricted GMP Certificate would be withdrawn based on the Mutual Recognition Agreement (MRA) and recent inspections conducted by the FDA.
HUNT VALLEY, Md., June 11, 2018 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a Contract Development Manufacturing Organization (CDMO) based in Hunt Valley, Maryland, received notification on June 4, 2018 from the Medicines and Health Care products Regulatory Agency (“MHRA”) that the previously restricted GMP Certificate would be withdrawn based on the Mutual Recognition Agreement (MRA) and recent inspections conducted by the FDA. The notification stated that “following confirmation from the USFDA, Pii sites at Hunt Valley (Pii1) and Cockeysville (Pii3) and associated laboratories and storage facilities are now considered to operate in general compliance with GMP.” The FDA conducted inspections of Pii in the fall of 2017 and recently issued Establishment Inspection Reports (“EIR”) associated with these inspections. The FDA also confirmed that Pii’s parenteral facility is now approved for product profile codes for both terminally sterilized products (SVT) and aseptically filled products (SVS).
The lifting of the restricted license means that any existing and future EU Marketing Authorization applications will now be supported by a Certificate of Pharmaceutical Product required from USFDA and any EU clinical trial applications will be supported by QP declaration for Import. Pii will be able to continue to support ongoing as well as new clinical studies in the US and EU for oral solid, liquid, topicals and injectable drug products.
Dr. Syed Abidi, Chairman and CEO, states “The withdrawal of the restricted license based on mutual recognition between MHRA and FDA demonstrates Pii’s commitment to regulatory compliance, with a focus on continuous quality improvements and strengthening of overall quality systems within the organization. Along with our partners, we’ve received FDA market approval for seven products and commercially launched six products in 2017. We anticipate approval of a minimum of three products by the end of the year.”
About Pharmaceutics International, Inc.
Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland USA, Pii’s services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances. For more information, please visit https://www.pharm-int.com.
Contact:
Syed E. Abidi, Ph.D., Chairman and CEO
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (410) 584-0001
Email: seabidi@pharm-int.com
View original content with multimedia: http://www.prnewswire.com/news-releases/pii-announces-positive-inspection-news-from-fda-and-mhra-300663945.html
SOURCE Pharmaceutics International, Inc.
